Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | CBR1 | P16152 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | ACLY | P53396 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 6/20 | 0.46 |
| ▸ | KIT | P10721 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pochonin D SCHEMBL4513578 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin D SCHEMBL2683508 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin D SCHEMBL10150436 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| Pochonin D SCHEMBL2683506 | 1.00 | HSP90AB1 (1.00) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL10150141 | 0.91 | HSP90AB1 (0.84) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL14293422 | 0.89 | HSP90AB1 (0.80) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL10150456 | 0.87 | HSP90AB1 (0.78) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL10150133 | 0.87 | HSP90AB1 (0.77) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL12142594 | 0.87 | HSP90AB1 (0.77) | HSP90AB1MAPTHSP90AA1GAARAB9A | |
| SCHEMBL2622305 | 0.86 | HSP90AB1 (0.76) | HSP90AB1MAPTHSP90AA1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119424412-A | Application of natural inhibitor taking PRDX1 as drug target in preparation of anti-breast cancer drugs | 中国药科大学 | 2025-02-14 | — | — | CN | claimed |
| US-20230390416-A1 | COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-12-07 | — | — | US | claimed |
| WO-2022082108-A1 | COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | claimed |
| WO-2012166617-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | CYTOCURE LLC (US) | 2012-12-06 | — | — | WO | claimed |
| CN-119424412-A | Application of natural inhibitor taking PRDX1 as drug target in preparation of anti-breast cancer drugs | 中国药科大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-119424412-A | Application of natural inhibitor taking PRDX1 as drug target in preparation of anti-breast cancer drugs | 中国药科大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240325368-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING A HEAT SHOCK PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024197097-A2 | COMPOSITIONS AND METHODS UTILIZING NOVEL MECHANISMS TARGETING CELL RESPONSES TO STRESS | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20230390416-A1 | COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-12-07 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2009105755-A2 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | NEXGENIX PHARMACEUTICALS (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008150302-A1 | TREATMENT OF NEUROFIBROMATOSIS WITH RADICICOL AND ITS DERIVATIVES | NEXGENIX PHARMACEUTICALS (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008143647-A2 | METHODS OF TREATING VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021213-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | WINSSINGER NICOLAS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325368-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING A HEAT SHOCK PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HSPE1, HSPD1, HSPA2 | HSP90AB1 7/4885MAPT 4034/4885HSP90AA1 4/4885 |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | HSP90AB1 31/4885MAPT 3619/4885HSP90AA1 14/4885 |
| US-20230390416-A1 | COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885MAPT 2364/4885HSP90AA1 2/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | HSP90AB1 2171/4885MAPT 4173/4885HSP90AA1 2387/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885MAPT 1982/4885HSP90AA1 2/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | HSP90AB1 3627/4885MAPT 2470/4885HSP90AA1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.